RHYTHM PHARMACEUTICALS, INC.
About RHYTHM PHARMACEUTICALS, INC.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $189.8M
- Net income
- -$196.5M
- Total assets
- $480.2M
- Market cap
- $5.9B
- Gross margin
- 89.7%
- Operating margin
- -101.2%
- Net margin
- -103.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $189.8M
- Cost of revenue
- $19.5M
- Gross profit
- $170.3M
- Operating expenses
- $362.3M
- Operating income
- -$192.0M
- Income tax
- $497.0K
- Net income
- -$196.5M
- EPS (basic)
- $-3.11
- EPS (diluted)
- $-3.11
Balance sheet
- Total assets
- $480.2M
- Current assets
- $466.9M
- Total liabilities
- $210.2M
- Current liabilities
- $105.9M
- Shareholders’ equity
- $139.1M
Cash flow
- Operating cash flow
- -$115.7M
- Investing cash flow
- -$137.2M
- Financing cash flow
- $218.0M
- Net cash flow
- -$34.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $5.9B
- EPS (diluted)
- $-3.11
- Shares outstanding
- 69.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 5, 2017
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $196.5M in FY2025.
- Revenue grew 5916% from FY2021 to FY2025.
- Gross margin of 89.7%, net margin -103.6%.
- Trading 27% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review RHYTHM PHARMACEUTICALS, INC..
Write a review
News about RHYTHM PHARMACEUTICALS, INC.
News & sentiment via Polygon.io
